findings of the study titled "Cardiovascular Safety of Lorcaserin in Overweight
or Obese Patients" is published in the
of occurrence of adverse heart
events compared to placebo.
and reduces appetite.
‘Lorcaserin aided sustained weight loss in overweight/obese patients without an increased rate of adverse heart events such as heart attack or stroke when compared to placebo.’
weight loss drugs such as fenfluramine
and its derivatives
rapidly caused serious heart complications such as pulmonary hypertension and damage to heart
. Another agent rimonabant
found to be safe from a heart point of view but led to severe psychiatric issues
. Both these drugs and their derivatives
were subsequently withdrawn from the market.
harmful occurrences such as the above, the FDA has now approved weight-loss agents
subject to the condition that post market safety clinical trials can prove
that these agents do not cause a higher rate of adverse heart related effects.
Benefits of Various
Weight Loss Strategies In Reducing Adverse Heart Related Events
various weight loss strategies include lifestyle modifications, medications and
bariatric or weight loss surgery.
- Interestingly, none of the specific lifestyle modifications or medications
(including lorcaserin) used as weight-loss strategy that have been studied
so far have shown a reduction in
- Lorcaserin is found to promote sustained weight loss without
a higher rate (but not significant reduction) of occurrence of adverse
heart events compared to placebo
- It is thus possible that weight
loss alone does not influence risk of major adverse heart related
events or it is possible that the slight weight reductions typically seen
with medications or lifestyle measures must be sustained over a prolonged
period of time to actually reduce heart disease risk
studies of bariatric surgery (which offer a
higher rate of sustained weight loss than pharmacologic or
lifestyle-modification strategies), have shown a reduction of
adverse heart related events including death, heart attack, stroke,
and heart failure over a follow-up period of 10 to 20 years
- However, randomized trials (which are considered the gold standard) of bariatric surgery conducted so
far have not demonstrated the
statistical power needed to measure the association between bariatric
surgery and reduction in adverse heart events
conclusion, it can be said that the CAMELLIA-TIMI 61 study finds that lorcaserin
offers sustained weight loss in high risk overweight or obese patients
a notable increase in unfavorable events compared to placebo.
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients - (https://www.nejm.org/doi/full/10.1056/NEJMoa1808721)